US FDA inspection at Gland Pharma's Dundigal facility, Hyderabad
The company has received 1 (ONE) observation on Form 483 with respect to ANDA filed for the product to be manufactured at the said Facility.
The company has received 1 (ONE) observation on Form 483 with respect to ANDA filed for the product to be manufactured at the said Facility.
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
Subscribe To Our Newsletter & Stay Updated